What it's for (Indications)
- Clobetasol propionate + salicylic acid combination therapy is indicated for the short-term treatment of inflammatory and hyperkeratotic dermatoses that are responsive to topical corticosteroids, particularly those characterized by significant scaling and thickening of the skin.
- This includes conditions such as severe chronic plaque psoriasis, intractable eczemas, and other hyperkeratotic inflammatory skin conditions that have not adequately responded to less potent corticosteroid preparations.
- The salicylic acid component aids in descaling, reducing hyperkeratosis, and enhancing the penetration of clobetasol propionate, thereby augmenting its anti-inflammatory and antiproliferative effects.
- Treatment should be initiated and supervised by a physician experienced in managing such dermatological conditions.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | A thin layer of the clobetasol propionate + salicylic acid ointment or cream should be applied to the affected skin areas once or twice daily, as directed by a healthcare professional. The treatment duration should be limited to the shortest possible time, typically not exceeding two consecutive weeks for adults and generally not more than four weeks in total, to minimize the risk of systemic absorption and local adverse effects. The total weekly dosage should not exceed 50 grams of the preparation. Occlusive dressings should generally be avoided unless specifically instructed by a physician, as occlusion significantly increases the percutaneous absorption of both active ingredients. Application to large surface areas of the body should also be avoided. Hands should be washed thoroughly after application, unless the hands are the area being treated. Pediatric use is generally discouraged due to increased susceptibility to systemic toxicity. |
Safety & Warnings
Common Side Effects
- Common local side effects associated with clobetasol propionate + salicylic acid include burning, stinging, itching, irritation, dry skin, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, and secondary infection.
- More severe local effects, particularly with prolonged use or under occlusion, can include skin atrophy (thinning), striae (stretch marks), telangiectasia (spider veins), and purpura.
- Systemic absorption of clobetasol propionate can lead to HPA axis suppression, manifestations of Cushing's syndrome (e.
- g.
- , central obesity, moon face, striae), hyperglycemia, glucosuria, and, in rare cases, growth retardation in children.
- Ocular effects such as cataracts and glaucoma may also occur, especially with periocular application or extensive systemic absorption.
- Systemic absorption of salicylic acid, particularly when applied to large areas or compromised skin, can lead to salicylism, characterized by symptoms like tinnitus, dizziness, headache, confusion, nausea, vomiting, and hyperventilation.
- Patients should be advised to report any adverse reactions promptly.
Serious Warnings
- Black Box Warning: Clobetasol propionate, a super-high potency topical corticosteroid, carries a substantial risk of inducing hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glaucoma. These systemic effects are particularly prominent with prolonged use, application to large body surface areas, use under occlusive dressings, and in pediatric patients due to their higher surface area to body weight ratio. Such systemic absorption can lead to serious, potentially irreversible adverse effects. Patients should be carefully monitored for signs and symptoms of HPA axis suppression, and treatment duration should be strictly limited, typically to two consecutive weeks and generally not exceeding four weeks, with the total weekly dosage restricted to 50 grams or less. Abrupt discontinuation after prolonged use can precipitate a rebound flare of the underlying dermatosis. The concomitant use of salicylic acid in this formulation may enhance the percutaneous absorption of clobetasol propionate, increasing the potential for systemic toxicity. Additionally, extensive application of salicylic acid can lead to systemic salicylism, characterized by symptoms such as tinnitus, dizziness, headache, nausea, and confusion, particularly in patients with compromised renal function.
- Patients receiving clobetasol propionate + salicylic acid should be warned about the potential for significant systemic absorption, leading to HPA axis suppression, Cushing's syndrome, and hyperglycemia.
- This risk is amplified with prolonged treatment, application to large body surface areas, use of occlusive dressings, and in pediatric patients.
- Abrupt withdrawal after prolonged therapy may precipitate adrenal insufficiency.
- Visual disturbances, including blurred vision, cataracts, and glaucoma, have been reported with corticosteroid use and warrant ophthalmologic evaluation.
- Local skin reactions, such as atrophy, striae, and telangiectasia, are more likely with prolonged or inappropriate use, especially on sensitive skin areas.
- The preparation should not be applied to the face, groin, or axillae, or used for the treatment of rosacea or perioral dermatitis.
- Salicylic acid can cause local irritation and, if absorbed systemically in large quantities, can lead to salicylism, especially in patients with impaired renal function or those concurrently taking other salicylates.
- The combination may mask the signs of infection; if secondary infection develops, appropriate antimicrobial therapy should be instituted.
- If irritation or sensitization develops, treatment should be discontinued.
How it Works (Mechanism of Action)
The therapeutic action of clobetasol propionate + salicylic acid is attributed to the synergistic effects of its two active components.
* **Clobetasol Propionate:** This is a synthetic corticosteroid of super-high potency. Its primary mechanism involves binding to glucocorticoid receptors in the cytoplasm, leading to the formation of a steroid-receptor complex that translocates into the nucleus. This complex modulates gene expression by either activating or repressing transcription of specific genes. Clobetasol exerts anti-inflammatory, antipruritic, and vasoconstrictive effects. It suppresses the immune response by inhibiting the synthesis and release of various inflammatory mediators (e.g., prostaglandins, leukotrienes, histamine) and by reducing the activity of immune cells (e.g., T-lymphocytes, macrophages). It also induces lipocortins, which inhibit phospholipase A2, thereby preventing the release of arachidonic acid, a precursor to inflammatory mediators.
* **Salicylic Acid:** As a keratolytic agent, salicylic acid works by dissolving the intercellular cement substance that binds scales in the stratum corneum, promoting desquamation and loosening of keratinized cells. This action reduces hyperkeratosis and makes the skin smoother. Additionally, the keratolytic effect of salicylic acid enhances the penetration of clobetasol propionate into the epidermis, thereby increasing its therapeutic efficacy in conditions characterized by thick, scaly lesions. Salicylic acid also possesses mild antiseptic properties.
Commercial Brands (Alternatives)
No other brands found for this formula.